Nuveen
AVXL icon

Nuveen’s Anavex Life Sciences AVXL Stock Holding History

Nuveen’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Buy
182,722
+13,566
+8% +$40.1K ﹤0.01% 3297
2026
Q1 		$519K Buy
169,156
+779
+0.5% +$3.37K ﹤0.01% 2822
2025
Q4 		$599K Hold
168,377
– – ﹤0.01% 2807
2025
Q3 		$1.5M Hold
168,377
– – ﹤0.01% 2426
2025
Q2 		$1.55M Sell
168,377
-20,664
-11% -$176K ﹤0.01% 2414
2025
Q1 		$1.62M Buy
189,041
+10,076
+6% +$95.1K ﹤0.01% 2424
2024
Q4 		$1.92M Hold
178,965
– – ﹤0.01% 2406
2024
Q3 		$1.02M Sell
178,965
-125,200
-41% -$722K ﹤0.01% 2752
2024
Q2 		$1.28M Buy
304,165
+38,373
+14% +$155K ﹤0.01% 2604
2024
Q1 		$1.35M Buy
265,792
+25,351
+11% +$143K ﹤0.01% 2571
2023
Q4 		$2.24M Buy
240,441
+13,819
+6% +$95.1K ﹤0.01% 2362
2023
Q3 		$1.48M Buy
226,622
+14,155
+7% +$113K ﹤0.01% 2414
2023
Q2 		$1.73M Buy
212,467
+1,065
+0.5% +$9.13K ﹤0.01% 2415
2023
Q1 		$1.81M Sell
211,402
-9,678
-4% -$96.6K ﹤0.01% 2369
2022
Q4 		$2.05M Sell
221,080
-50,375
-19% -$538K ﹤0.01% 2380
2022
Q3 		$2.8M Sell
271,455
-3,575
-1% -$37.7K ﹤0.01% 2216
2022
Q2 		$2.75M Buy
275,030
+1,299
+0.5% +$12.3K ﹤0.01% 2275
2022
Q1 		$3.43M Buy
273,731
+29,603
+12% +$364K ﹤0.01% 2264
2021
Q4 		$4.23M Buy
244,128
+18,460
+8% +$351K ﹤0.01% 2220
2021
Q3 		$4.05M Sell
225,668
-9,150
-4% -$182K ﹤0.01% 2328
2021
Q2 		$5.37M Sell
234,818
-16,789
-7% -$249K ﹤0.01% 2203
2021
Q1 		$3.76M Buy
251,607
+49,915
+25% +$545K ﹤0.01% 2307
2020
Q4 		$1.09M Buy
201,692
+1,605
+0.8% +$8.46K ﹤0.01% 2772
2020
Q3 		$910K Buy
200,087
+909
+0.5% +$3.91K ﹤0.01% 2728
2020
Q2 		$980K Sell
199,178
-12,512
-6% -$47.3K ﹤0.01% 2633
2020
Q1 		$667K Buy
211,690
+101,495
+92% +$354K ﹤0.01% 2669
2019
Q4 		$285K Hold
110,195
– – ﹤0.01% 3024
2019
Q3 		$348K Hold
110,195
– – ﹤0.01% 3028
2019
Q2 		$372K Buy
+110,195
New +$342K ﹤0.01% 3088

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's AVXL Position: Q2 2026 in Review

Nuveen increased its Anavex Life Sciences (AVXL) stake by 8% in Q2 2026, buying an estimated $40.1K and bringing the position to 182,722 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #3297.

Nuveen first reported a position in AVXL in Q2 2019 and has held it in 29 quarters since. The position peaked at $5.37M in Q2 2021. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Nuveen held 182,722 shares of Anavex Life Sciences worth $473K as of Q2 2026.
  • Nuveen bought 13,566 Anavex Life Sciences shares in Q2 2026, an estimated $40.1K.
  • Anavex Life Sciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3297 holding.
  • Nuveen first reported a position in Anavex Life Sciences in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Anavex Life Sciences position peaked at $5.37M in Q2 2021.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.